Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues

David H. Coy, Chester Meyers, Akira Arimura, Andrew V Schally, Tommie W. Redding

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.

Original languageEnglish
Pages (from-to)1407-1410
Number of pages4
JournalMetabolism
Volume27
Issue number9 SUPPL. 1
DOIs
StatePublished - Jan 1 1978
Externally publishedYes

Fingerprint

Somatostatin
Glucagon
Growth Hormone
Insulin
Pancreatic Hormones
Motilin
Gastrointestinal Hormones
Peptides
Secretin
Gastric Acid
Gastrins
Thyrotropin
Half-Life
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues. / Coy, David H.; Meyers, Chester; Arimura, Akira; Schally, Andrew V; Redding, Tommie W.

In: Metabolism, Vol. 27, No. 9 SUPPL. 1, 01.01.1978, p. 1407-1410.

Research output: Contribution to journalArticle

Coy, David H. ; Meyers, Chester ; Arimura, Akira ; Schally, Andrew V ; Redding, Tommie W. / Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues. In: Metabolism. 1978 ; Vol. 27, No. 9 SUPPL. 1. pp. 1407-1410.
@article{6c9588fd75b3492ab2041707826dae61,
title = "Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues",
abstract = "Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.",
author = "Coy, {David H.} and Chester Meyers and Akira Arimura and Schally, {Andrew V} and Redding, {Tommie W.}",
year = "1978",
month = "1",
day = "1",
doi = "10.1016/0026-0495(78)90083-5",
language = "English",
volume = "27",
pages = "1407--1410",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "9 SUPPL. 1",

}

TY - JOUR

T1 - Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues

AU - Coy, David H.

AU - Meyers, Chester

AU - Arimura, Akira

AU - Schally, Andrew V

AU - Redding, Tommie W.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.

AB - Somatostatin was isolated from extracts of ovine1 and porcine2 hypothalamic tissue and was found to be a cyclic tetradecapeptide with the following sequence: {A figure is presented} Subsequent studies revealed that the peptide not only had inhibiting effects on growth hormone (GH) release, but also on pituitary thyrotropin (TSH) and a large array of gastrointestinal and pancreatic hormones, including insulin, glucagon, gastrin and gastric acid, secretin, CCK, GIP, VIP, and motilin. These activities have been recently reviewed.3. The therapeutic value of somatostatin in several important areas is diminished by its broad spectrum of activities. As with most naturally occurring peptides, somatostatin also has a short biologic half-life, 4 making its long-term use impractical. Therefore, analogues are being designed for enhanced, prolonged, and selective activities. In addition, competitive inhibitors of somatostatin could be of great interest and pharmacologic value.

UR - http://www.scopus.com/inward/record.url?scp=0018072227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018072227&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(78)90083-5

DO - 10.1016/0026-0495(78)90083-5

M3 - Article

C2 - 683009

AN - SCOPUS:0018072227

VL - 27

SP - 1407

EP - 1410

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 9 SUPPL. 1

ER -